Synthetic Alternatives to Fetal Bovine Serum: Platforms, Technologies, and Prospects for Industrial Vaccine Production
Biotechnology and Bioengineering · 31.07.2026
DOI: 10.1002/bit.70324 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 31.07.2026. Verfasst von Sanjay Gottipamula und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cell Space Research Centre Pvt. Ltd., Malur, Karnataka, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: Cell Space Research Center Pvt. Ltd.
Abstract (Originalsprache)
Fetal Bovine Serum (FBS) has served as the gold standard supplement in mammalian cell cultures for more than six decades due to its cocktail of growth factors, carrier proteins, hormones, and attachment factors that create an ideal proliferative microenvironment. Nevertheless, heightened regulatory pressure, ethical issues associated with the use of bovine fetuses, logistical challenges, batch‐to‐batch variations, and the risks of contamination by adventitious agents have driven the need to formulate synthetic, animal‐origin‐free (AOF) substitutes. This review examines the key technologies being explored to engineer FBS substitutes, including chemically defined media, recombinant protein fortification using precision fermentation, hydrolyzed plants, human platelet lysates (HPL), conditioned media derived from induced pluripotent stem cells (iPSCs), and genetically engineered microbial cell factories, with special consideration of their feasibility for large‐scale vaccine production in Vero, BHK‐21, HEK293, and MDCK cells. No single technology can presently replace FBS across all applications; however, the convergence of biologics, chemically defined media, and precision fermentation platforms promises to bridge this gap.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cell Space Research Centre Pvt. Ltd., Malur, Karnataka, India.
- Brains Super Speciality Hospital, Bengaluru, Karnataka, India.
ORCID-Profile: Sanjay Gottipamula
Förderung
- Cell Space Research Center Pvt. Ltd
Zitieren
APA
Gottipamula, S., & Neelam Krishnan, V. (2026). Synthetic Alternatives to Fetal Bovine Serum: Platforms, Technologies, and Prospects for Industrial Vaccine Production. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70324
Vancouver
Gottipamula S, Neelam Krishnan V. Synthetic Alternatives to Fetal Bovine Serum: Platforms, Technologies, and Prospects for Industrial Vaccine Production. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70324
BibTeX
@article{Gottipamula2026,
author = {Gottipamula, Sanjay and Neelam Krishnan, Venkataramana},
title = {Synthetic Alternatives to Fetal Bovine Serum: Platforms, Technologies, and Prospects for Industrial Vaccine Production},
journal = {Biotechnology and Bioengineering},
year = {2026},
doi = {10.1002/bit.70324}
}
EUVIMED